Amberchrom is a little further up the supply chain. It's the actual polymer manufactured by Dow Chemical for use in the CytoSorb HemoDefend products.
When Missourii Pacific merged with the smaller Union Pacific under the Union Pacific name, MoPac's CEO headed the combined company.
You say you have been a CTSO investor for six years. Back that long ago, we had a voice of reason (also an ICU nurse) sharing professional insight in a patient (no pun intended) manner somewhat resembling yours. She used the alias kastlem but stopped posting in 2010. No offense intended, but since meso.dedo is a relatively new alias, were you kastlem? Granted, there could be dozens, if not hundreds, of such nurses following CTSO.
We can believe everything we read at Motley Fool and Seeking Alpha, right? Those articles are just the conclusions of other amateurs like us, based on the facts (and opinions) they choose to incorporate in their arguments and those they choose to discount.
Now there's a credible possibility Suspected only private equity would (1) send a letter, (2) make a lowball offer and (3) leak the rumor.
FWIW MF says $18B was the reported offer. That's less than $47 a share. Either the report is erroneous or somebody has a lot of chutzpah to offer the current market cap in a severe oil patch recession.
ah pulled his orders? The man of the disciplined investing style? Did he say why he pulled the orders, besides the disconnect between a $2 dividend and $60-something share price for a company not in distress?
Maybe it's a Bill Klesse hangover. I like Joe Gorder and his background but would venture a guess the market may have more warmly embraced an outsider as Klesse's successor as an indicator VLO really was headed in a different direction. .
Was multi-tasking while listening to the call, but did I hear mention of new debt and equity? What was the context of that discussion?
Dividend announcements were on Nov 8 and Nov 7 in 2013 and 2012, respectively, both dates of which were after the dates quarterly earnings were released. Depends on when the board meets.
The share price has not reacted much in either direction on the dates quarterly earnings were released for several years. Investor Relations must have been doing an excellent job communicating with both sell-side and buy-side analysts. Not expecting any fireworks.
Google "Blood-cleansing biospleen device developed for sepsis therapy" and read the Sep 14, 2014 press release issued by the Wyss Institute. Also, view the embedded photograph of the device and the video commentary.
The Wyss Institute's device removes pathogens rather than cytokines and bears no resemblance to the Cytosorb cartridge in form or function that would infringe CTSO's patents.
There are two angles to the issue. Others, as evidenced by articles published across the pond, think the scandal could change the way European regulators and consumers think about diesel. The second angle is suggestion the gasoline-oriented refiners could benefit if the diesel market is diminished. Suppose we will have to wait to see how it plays out.
Knowing the US market is small, the question was more focused on the European market, both in terms of Pembroke and exports.